Development of the Paris definition of early Crohn's disease for disease-modification trials: Results of an international expert opinion process

American Journal of Gastroenterology

Volumn 107, Issue 12, 2012, Pages 1770-1776

  Peyrin Biroulet, Laurent ^a   Billioud, Vincent ^a   D'Haens, Geert ^b   Panaccione, Remo ^c   Feagan, Brian ^d   Panés, Julian ^e   Danese, Silvio ^f   Schreiber, Stefan ^g   Ogata, Haruhiko ^h   Hibi, Toshifumi ^h   Higgins, Peter D R ⁱ   Beaugerie, Laurent ^j   Chowers, Yehuda ^k,l   Louis, Edouard ^m   Steinwurz, Flávio ⁿ   Reinisch, Walter ^o   Rutgeerts, Paul ^p   Colombel, Jean Frédéric ^q   Travis, Simon ^r   Sandborn, William J ^s  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY OF CALGARY   (Canada)

^d ROBARTS RESEARCH INSTITUTE   (Canada)

^e INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^f HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^h KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^j ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^k RAMBAM MEDICAL CENTER   (Israel)

^l TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^m UNIVERSITY OF LIÈGE   (Belgium)

ⁿ HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^o MEDICAL UNIVERSITY OF VIENNA   (Austria)

^p UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^q UNIV LILLE   (France)

^r JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^s UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BIOLOGICAL PRODUCT; CORTICOSTEROID; MERCAPTOPURINE; MESALAZINE; METHOTREXATE;

AGE; ARTICLE; CLINICAL TRIAL (TOPIC); COLON RESECTION; COLON SURGERY; COLONOSCOPY; CONSENSUS DEVELOPMENT; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE DURATION; EARLY CROHN DISEASE; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE FUNCTION; INTESTINE INJURY; MEDICAL EXPERT; NOMENCLATURE; PRIORITY JOURNAL;

CLINICAL TRIALS AS TOPIC; CONCEPT FORMATION; CONSENSUS; CROHN DISEASE; DISEASE PROGRESSION; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERNATIONAL COOPERATION; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84859072629     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2012.117     Document Type: Article

References (42)

1. Pariente B, Cosnes J, Danese S et al. Development of the Crohn's disease digestive damage score, the Lemann score. Inflamm Bowel Dis 2011;17:1415-22.
2. Peyrin-Biroulet L, Cieza A, Sandborn WJ et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut 2012;61:241-7.
3. Peyrin-Biroulet L, Cieza A, Sandborn WJ et al. Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. Inflamm Bowel Dis 2010;16:15-22.
4. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF et al. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2009;105:289-97.
5. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF et al. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. Inflamm Bowel Dis 2011;17:471-8.
6. Aletaha D, Neogi T, Silman AJ et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
7. Ma MH, Kingsley GH, Scott DL. A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2009;49:91-8.
8. Resman-Targoff BH, Cicero MP. Aggressive treatment of early rheumatoid arthritis: recognizing the window of opportunity and treating to target goals. Am J Manag Care 2010;16(Suppl):S249-58.
9. Comi G. Why treat early multiple sclerosis patients? Curr Opin Neurol 2000;13:235-40.
10. Goodin DS, Bates D. Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode. Mult Scler 2009;15:1175-82.
11. D'Haens G, Baert F, van Assche G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-7.
12. Ananthakrishnan AN, Binion DG. Improved efficacy of biological maintenance therapy in "early" compared with "late" Crohn's disease: strike while the iron is hot with anti-TNF agents? Am J Gastroenterol 2010;105:1583-5.
13. Peyrin-Biroulet L. Why should we define and target early Crohn's disease? Gastroenterol Hepatol (NY) 2011;7:324-6.
14. Bamias G, Martin C, Mishina M et al. Proinflammatory effects of TH2 cytokines in a murine model of chronic small intestinal inflammation. Gastroenterology 2005;128:654-66.
15. Cominelli F. Early and late gut immune responses in IBD. J Pediatr Gastroenterol Nutr 2008;46(Suppl 1):E20.
16. Desreumaux P, Brandt E, Gambiez L et al. Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology 1997;113:118-26.
17. Kugathasan S, Saubermann LJ, Smith L et al. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut 2007;56:1696-705.
18. Rivera-Nieves J, Ho J, Bamias G et al. Antibody blockade of CCL25/CCR9 ameliorates early but not late chronic murine ileitis. Gastroenterology 2006;131:1518-29.
19. Spencer DM, Veldman GM, Banerjee S et al. Distinct inflammatory mechanisms mediate early versus late colitis in mice. Gastroenterology 2002;122:94-105.
20. Johnson LA, Luke A, Sauder K et al. Intestinal fibrosis is reduced by early elimination of inflammation in a mouse model of IBD: impact of a "top-down" approach to intestinal fibrosis in mice. Inflamm Bowel Dis 2012;18:460-71.
21. Lionetti P, Bronzini F, Salvestrini C et al. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther 2003;18:425-31.
22. Sandborn WJ, Panaccione R, Thakkar R et al. Crohn's disease mucosal healing in adalimumab-treated patients is affected by disease duration: results from EXTEND [abstr]. Gastroenterology 2010;138(Suppl 1):S-164.
23. Schreiber S, Reinisch W, Colombel J et al. Early Crohn's disease shows high levels of remission to therapy with adalimumab: sub-analysis of CHARM [abstr]. Gastroenterology 2007;132(Suppl 1):A-147.
24. Schreiber S, Colombel JF, Bloomfield R et al. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol 2010;105:1574-82.
25. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF et al. Early Crohn disease: a proposed definition for use in disease-modification trials. Gut 2010;59:141-7.
26. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989;24(Suppl 170):2-6; discussion 16-19.
27. Daperno M, D'Haens G, Van Assche G et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004;60:505-12.
28. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Gut 1989;30:983-9.
29. Rimola J, Ordas I, Rodriguez S et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis 2011;17:1759-68.
30. Best WR, Becktel JM, Singleton JW et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
31. Fukuya T, Hawes DR, Lu CC et al. CT diagnosis of small-bowel obstruction: efficacy in 60 patients. AJR Am J Roentgenol 1992;158:765-9.
32. Khurana B, Ledbetter S, McTavish J et al. Bowel obstruction revealed by multidetector CT. AJR Am J Roentgenol 2002;178:1139-44.
33. Adler J, Swanson SD, Schmiedlin-Ren P et al. Magnetization transfer MRI: a non-invasive method to identify and quantitate intestinal fibrosis in Crohn's disease. Radiology 2011;259:127-35.
34. Stidham RW, Xu J, Johnson LA et al. Ultrasound elasticity imaging for detecting intestinal fibrosis and inflammation in rats and humans with Crohn's disease. Gastroenterology 2011;141:819-26.
35. Vavricka SR, Spigaglia SM, Rogler G et al. Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:496-505.
36. Faubion WA Jr, Loftus EV Jr, Harmsen WS et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-60.
37. Thia KT, Sandborn WJ, Harmsen WS et al. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 2010;139:1147-55.
38. Colombel J-F, Rutgeerts PJ, Sandborn WJ et al. Adalimumab treatment results in deep remission for patients with moderate to severe ileocolonic Crohn's disease: results from EXTEND [abstr]. Gastroenterology 2010;138(Suppl 1):S-518.
39. Panes J, Bouzas R, Chaparro M et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. Aliment Pharmacol Ther 2011;34:125-45.
40. Lapidus A. Crohn's disease in Stockholm County during 1990-2001: an epidemiological update. World J Gastroenterol 2006;12:75-81.
41. Schwartz DA, Loftus EV Jr, Tremaine WJ et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 2002;122:875-80.
42. Beaugerie L, Seksik P, Nion-Larmurier I et al. Predictors of Crohn's disease. Gastroenterology 2006;130:650-6.